• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Mirati - oncology?

Quote
















anonymous said:
Meek is an imbecile. Clementia. Google it.
Click to expand...

Meek’s handiwork.

The EMA said on its website that it could not draw any firm conclusions on the benefits of the French biopharma’s Sohonos (palovarotene), which selectively targets the retinoic-acid receptor gamma (RARγ), “as the applicant’s conclusion was based on a post-hoc analysis which was neither scientifically nor clinically justified and pre-specified study objectives were not met.”
 
















One time Phil was at the blackjack table and screemed, "sanna manna koofa....I cant do this!!!"...Then started to sing "We didnt start the fire" by Billy Joel. What a night we did not plan for!
 
















anonymous said:
It would be wise for the enlightened to sharpen your resumes.
When the full quarter sales for adagrasib are announced in April, be prepared for a significant reduction in work force.
Leadership will strip all “non-essential” workforce to prepare for an acquisition or merger.

If you see this as an opportunity from a stock pricing perspective, you are sorely misguided. The price will be bargain basement at best. Don't worry though. Leadership will do very well for themselves....
Click to expand...

Totally. The head of HR has a plan is in place already and AMGENs likely price reductions will make it impossible for us to compete now - they are already removing people gradually. Everyone is blaming Meek ??? - Baum and Hickey are equally to blame. How that poisonous midget Covello has survived for so long with her shitty leadership amazes us all - she has more staff casualties than any other department and really poor staff morale, staff gender selection bias issues, but seems to get away with it all.
 




anonymous said:
Totally. The head of HR has a plan is in place already and AMGENs likely price reductions will make it impossible for us to compete now - they are already removing people gradually. Everyone is blaming Meek ??? - Baum and Hickey are equally to blame. How that poisonous midget Covello has survived for so long with her shitty leadership amazes us all - she has more staff casualties than any other department and really poor staff morale, staff gender selection bias issues, but seems to get away with it all.
Click to expand...
Gingervitas is perfectly treatsable
 








anonymous said:
Meep has made a mockery of this company! Cut em aloose!
Click to expand...


Why is Bill Trebesky still in charge of technical operations?!!!!
Under qualified with no scientific clue. He is only good for shipping from location a to X. Him and his team still fumble!!!

Tired of dumbing down CMC for him so he can have a bit of a clue and saving his job because he has NO clue. Worst promotion in mirati.
 




anonymous said:
Meek’s handiwork.

The EMA said on its website that it could not draw any firm conclusions on the benefits of the French biopharma’s Sohonos (palovarotene), which selectively targets the retinoic-acid receptor gamma (RARγ), “as the applicant’s conclusion was based on a post-hoc analysis which was neither scientifically nor clinically justified and pre-specified study objectives were not met.”
Click to expand...

And Meek can add this type of value for Mirati too!
 












ab0281b0-a143-4e12-97d5-5a97b9dbf5b5_medium.png

All your base are belong to us
 




Top Bottom
Back
Quote